Headache and Migraine

Rimegepant, the only orally disintegrating anti-CGRP tablet, marketed as Nurtec ODT, will be available in a 75-mg dose.

Eptinezumab, Lundbeck’s intravenous monoclonal antibody that will be marketed as Vyepti, will become available for prescription in April 2020 with a recommended dose of 100 mg quarterly.

Two new classes of medications have quickly expanded the pool of available treatment options for patients with migraine, who now have more power than ever to choose the treatment that fits them best.

Eptinezumab, Lundbeck’s intravenous monoclonal antibody that will be marketed as Vyepti, will become available for prescription in April 2020 with a recommended dose of 100 mg quarterly.

Neurology News Network for the week ending February 22, 2020.

The model may help clinicians enact preventative measures for those with migraine with aura at an early stage.

The chronic migraine preventive, despite falling short of efficacy end points, was safe and well-tolerated in a small cohort of patients aged 12 to 17 years.

When compared with placebo, prophylactic pharmacologic treatments showed no significant long-term effects in pediatric patients with migraine.

Compared with healthy individuals, those with cluster headache are significantly more likely to experience sickness absence and disability pension days, with women more impacted than men.

Neurology News Network for the week ending February 8, 2020.

The director of headache services at NYU Langone discussed the 2019 American College of Emergency Physicians guidelines on acute nontraumatic headache in the emergency department.

Join NeurologyLive and the Women Neurologists Group on Twitter to celebrate women in neurology on National Women Physicians Day.

Neurology News Network for the week ending February 1, 2020.

The drug will be available in 50 mg and 100 mg oral tablets in pharmacies across the US in the coming days.

Teva announced that the Ajovy autoinjector is expected to be available to patients in the coming months.

Findings from a study revealed that 50% of strokes in adolescents remained cryptogenic, sparking the need for multidisciplinary collaboration on prevention and management.

Neurology News Network for the week ending January 27, 2020.

The Headaterm TENS device was shown to decrease pain at an 11.8% better rate than many acute migraine medications used in the emergency department in randomized trials, with data suggesting it is both effective and fast-acting.

Neurology News Network for the week ending January 18, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 17, 2020.

After first-step data suggested that one small molecule CGRP receptor antagonist and a monoclonal antibody against CGRP were successful and safe together in migraine. One of the study authors, Kathleen Mullin, MD, discussed the data.

Biohaven’s small molecule CGRP receptor antagonist rimegepant has displayed safety and efficacy in a small cohort of patients with migraine using it alongside erenumab.

Those achieving ≥50% response attained migraine reductions nearly double that of the full cohort, with data possibly providing context for setting realistic patient expectations regarding the spectrum of response.

Neurology News Network for the week ending January 11, 2020.

New 52-week data from an extension study has suggested that recently FDA-approved ubrogepant (Ubrelvy; Allergan) is safe and tolerable, with minimal treatment-related adverse events with 2 doses assessed.

The guidelines included a review of 23 studies, suggesting that patients with normal neurological examinations do not require neuroimaging assessments as part of migraine treatment.

The oral, dual-mechanism therapy from Axsome Therapeutics met both of its primary end points in the phase 3 MOMENTUM trial in acute migraine, and is expected to be filed with the FDA.

Lasmiditan was efficacious across a number of doses in patients with migraine regardless of prior good or insufficient response to triptan administration.

With a differential diagnosis that varies from patient to patient, identifying and treating vestibular migraine continues to challenge even the most experienced clinicians.

The approvals introduced several new classes of drugs, including the ditans and gepants in migraine, as well as novel formulations that can ease the administration of treatments for Parkinson disease and epilepsy.